Becton Dickinson Dividendos y recompras
Dividendo controles de criterios 5/6
Becton Dickinson es una empresa que paga dividendos con una rentabilidad actual de 2.36% que está bien cubierta por los beneficios. La próxima fecha de pago es en 30th September, 2026 con una fecha ex dividendo de 9th September, 2026.
Información clave
2.4%
Rentabilidad por dividendo
5.2%
Rendimiento de la recompra
| Rendimiento total para el accionista | 7.5% |
| Rendimiento futuro de los dividendos | 2.2% |
| Crecimiento de los dividendos | 4.6% |
| Próxima fecha de pago de dividendos | 30 Sep 26 |
| Fecha ex dividendo | 09 Sep 26 |
| Dividendo por acción | n/a |
| Ratio de pago | 72% |
Últimas actualizaciones de dividendos y recompras
Recent updates
Actualización de narrativa • Sep 05
BDX: Margin Execution And Capital Returns May Balance 2027 Utilization Concerns
Becton Dickinson's updated fair value estimate of about $196, compared with roughly $190 previously, reflects analysts' higher price targets in the $190 to $210 range and their focus on remaining margin opportunity, manufacturing scale, and potential for steadier mid single digit growth over time. Analyst Commentary Recent research on Becton Dickinson shows a mix of optimism and caution that centers on execution, margin potential, and how quickly growth goals can show up in reported results.
Actualización de narrativa • Aug 22
BDX: 2027 Utilization And Inflation Headwinds Will Cap Medium Term Upside
Becton Dickinson's fair value estimate moves to $170 from $161 as analysts point to a slightly lower discount rate, less severe revenue pressure, stronger projected profit margins, and a lower future P/E assumption supported by recent price target increases across several research firms. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism on the business model and caution on the pace of execution, especially over the next couple of years.Seeking Alpha • Aug 13
Becton Dickinson: An Earnings Beat Again As Diverse Clinical Portfolio Keeps On Growing
Summary Becton Dickinson gets its prior buy rating reaffirmed again, agreeing with the latest Wall St consensus. Key strengths are its diverse and growing clinical portfolio expected to drive further upside, while a favorable Fitch rating lowers balance sheet risk. Market performance vs the S&P 500 is improving again. Key sector risks such as regulations, recalls, and the cost of capex investment into R&D and infrastructure were addressed. Read the full article on Seeking AlphaActualización de narrativa • Aug 08
BDX: Q3 Execution And Capital Returns May Offset 2027 Utilization Risks
Becton Dickinson's analyst fair value estimate has moved higher by about $8 to $189.58 as analysts factor in recent price target increases, confidence in easing headwinds, and support from product growth drivers and capital allocation plans. Analyst Commentary Recent Street research on Becton Dickinson highlights a mix of optimism around execution and product-driven growth, alongside caution on utilization trends and longer-term margin pressure.Actualización de narrativa • Jul 21
BDX: FY26 Utilization And Inflation Risks Will Temper Execution Upside
Analysts have adjusted the fair value estimate for Becton Dickinson stock from $150 to $161, citing updated views on sector procedure volumes, utilization trends, inflation headwinds, and valuation as reflected in recent changes to Street price targets. Analyst Commentary Recent Street commentary on Becton Dickinson reflects a mix of views, and several bearish analysts are leaning toward more cautious stances as they reassess utilization trends, inflation pressures, and how much optimism is already priced into the stock.Actualización de narrativa • Jul 06
BDX: FY26 Execution And Utilization Risks Will Shape Balanced Outlook
Becton Dickinson's analyst fair value estimate has been revised down by $6 to $150 as analysts factor in slightly lower utilization expectations and more conservative longer term assumptions, even as they point to generally healthy procedure volumes and capital expenditure trends across the sector. Analyst Commentary Recent research on Becton Dickinson points to a more cautious tone, with several bearish analysts trimming price targets while still acknowledging generally healthy procedure volumes and capital expenditure trends across MedTech, Life Sciences Tools, and Diagnostics.
Actualización de narrativa • Jun 22
BDX: Raised FY26 EPS Guidance And Buybacks Will Support Underappreciated Setup
The analyst price target for Becton Dickinson has been reduced by about $36 per share as analysts factor in lower utilization trends, inflation headwinds into 2027, and more limited margin expansion assumptions across larger medtech companies. Analyst Commentary Recent research on Becton Dickinson reflects a mixed backdrop, with several firms trimming price targets to account for lower utilization trends and inflation pressure into 2027.Artículo de análisis • Jun 19
Becton Dickinson (BDX) Stock Could Be 20.6% Undervalued After Class I Spinal Tray Recalls
Becton Dickinson (BDX) has initiated several voluntary Class I sub-recalls of BD Spinal Tray products across the US after FDA inspections flagged acceptance testing deficiencies at a supplier of bupivacaine in dextrose. See our latest analysis for Becton Dickinson. Becton Dickinson's share price has been under pressure, with the stock down 26.14% on a year to date share price return and 6.59% over 90 days, even though the 1 year total shareholder return is 11.34%. This suggests momentum has...Actualización de narrativa • Jun 06
BDX: New Medtech Portfolio And Buybacks Will Support Future Repricing
The updated analyst price target narrative for Becton Dickinson reflects a reduction of about $11 per share. Analysts are balancing recent target cuts and rating resets with more moderate assumptions for profit margins and valuation multiples.Actualización de narrativa • May 22
BDX: FY26 Execution And Margin Resets Will Shape Balanced Risk Profile
Analysts have trimmed the implied fair value for Becton Dickinson by $1 to $156, reflecting updated assumptions for slower revenue growth, lower profit margins, and a higher future P/E multiple following a series of recent price target cuts and one modest increase across the Street. Analyst Commentary Recent Street research on Becton Dickinson has leaned cautious, with several bearish analysts trimming price targets while only one major firm made a modest upward adjustment.Artículo de análisis • May 19
Shareholders Will Be Pleased With The Quality of Becton Dickinson's (NYSE:BDX) Earnings
The subdued stock price reaction suggests that Becton, Dickinson and Company's ( NYSE:BDX ) strong earnings didn't...Actualización de narrativa • Apr 30
BDX: Cautious Reset In FY26 Expectations And Execution Risks Will Shape Outlook
Becton Dickinson's analyst price target has been reset from $183 to $157 as analysts factor in more cautious revenue growth, slightly softer profit margins, a higher discount rate, and a lower assumed future P/E multiple. Analyst Commentary Recent Street research around Becton Dickinson reflects a more cautious tone, with a series of price target resets and neutral stances shaping expectations for risk and reward.Actualización de narrativa • Apr 15
BDX: 2026 MedTech Setup And Buybacks Will Support Upside Potential
Analyst price targets for Becton Dickinson have edged lower, with the fair value estimate moving from about $196.08 to $192.31 as analysts factor in slightly higher discount rates, modestly softer revenue growth and profit margins, and a somewhat higher future P/E multiple. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess execution risks and valuation assumptions.Actualización de narrativa • Apr 01
BDX: 2026 MedTech Setup And Tuck In M&A Will Support Upside
Analysts have trimmed their average price target for Becton Dickinson by about $1, reflecting slightly lower fair value and P/E assumptions, along with modestly higher profit margin expectations. Analyst Commentary Recent Street research on Becton Dickinson has featured several price target changes and rating actions that point to a mix of optimism about execution and caution around valuation and growth assumptions.Actualización de narrativa • Mar 18
BDX: 2026 MedTech Setup And Tuck In M&A Will Drive Upside
Narrative Update The latest analyst work on Becton Dickinson points to a mixed shift in price targets, with some firms raising their views by $12.30 to $15.00 while others trimmed estimates by $1.00 to $38.00, as analysts reassessed near term pressures, longer term MedTech prospects into 2026, and valuation assumptions including discount rate and future P/E inputs. Analyst Commentary Recent Street research on Becton Dickinson points to a split view, with some analysts lifting targets and others trimming them as they rework models for 2025 pressures and the setup into 2026.Actualización de narrativa • Mar 04
BDX: 2026 MedTech Setup And Buybacks Will Shape Upside Potential
The analyst price target for Becton Dickinson has been adjusted to approximately $197 from about $195, as analysts factor in recently updated views on large cap MedTech setups, leading to slightly higher fair value and P/E assumptions. Analyst Commentary Recent research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess large cap MedTech names and Becton Dickinson's role within that group.Actualización de narrativa • Feb 17
BDX: 2026 Reset With Mixed Research And Product Pipeline Will Shape Returns
Analysts have trimmed their average price target on Becton Dickinson by about $9 to reflect more cautious assumptions on revenue growth and margins. This is partly offset by a willingness to apply a higher future P/E multiple as recent research updates reset expectations across the sector.Actualización de narrativa • Feb 03
BDX: FY26 Guidance Reset Will Support More Constructive 2026 MedTech Setup
Narrative update The analyst price target for Becton Dickinson has been revised from about US$322 to about US$253. Analysts cite updated assumptions for growth, margins and future P/E, and they also reflect mixed recent Street research that includes both target raises and cuts following FY26 guidance and Q4 results.Artículo de análisis • Jan 31
Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05
Becton, Dickinson and Company's ( NYSE:BDX ) investors are due to receive a payment of $1.05 per share on 31st of...Actualización de narrativa • Jan 19
BDX: FY26 Reset And Alaris China And Vaccine Headwinds Will Pressure Outlook
Analysts have modestly adjusted their price expectations for Becton Dickinson, with recent Street targets ranging from a reduction to $202 to an increase to $215. They are balancing near term headwinds in areas like Alaris, China, and vaccines against what some see as a more constructive setup heading into 2026 for large cap MedTech.Actualización de narrativa • Jan 05
BDX: 2026 Reset And Headwinds Will Shape Fairly Balanced Return Potential
Analysts have modestly adjusted their fair value estimate for Becton Dickinson to about $205 per share, reflecting updated views on slower profit margin assumptions, a somewhat higher future P/E, and recent price target resets around $202 to $210 following Q4 results and FY26 guidance. Analyst Commentary Recent Street research has focused on how Becton Dickinson's latest Q4 results and FY26 outlook feed into valuation, execution risk, and growth expectations.Actualización de narrativa • Dec 21
BDX: FY26 Reset And Business Separation Will Shape Balanced Risk Reward Outlook
We raise our fair value estimate for Becton Dickinson to $183 from $172 per share, reflecting analysts' view that a conservative FY26 reset, modestly higher long term profitability, and a slightly richer future earnings multiple more than offset near term revenue growth headwinds and higher risk premia embedded in the discount rate. Analyst Commentary Bearish analysts are converging around a more cautious outlook for Becton Dickinson, trimming price targets and highlighting execution risks that could cap near term upside.Actualización de narrativa • Dec 07
BDX: 2026 Separation And Reset Outlook Will Shape Returns Amid Headwinds
Analysts have modestly lowered their price target on Becton Dickinson to about $203 per share from roughly $201 previously. This reflects slightly higher long term revenue growth assumptions, offset by a marginally lower profit margin outlook and cautious views on FY26 guidance amid Alaris, China, and vaccine related headwinds.Artículo de análisis • Nov 24
Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05
The board of Becton, Dickinson and Company ( NYSE:BDX ) has announced that it will be paying its dividend of $1.05 on...Actualización de narrativa • Nov 23
BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds
Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.Artículo de análisis • Nov 16
Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings
Soft earnings didn't appear to concern Becton, Dickinson and Company's ( NYSE:BDX ) shareholders over the last week. We...Artículo de análisis • Nov 09
Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05
Becton, Dickinson and Company ( NYSE:BDX ) will increase its dividend on the 31st of December to $1.05, which is 1.0...Actualización de narrativa • Nov 07
BDX Will Unlock New Growth Following Planned 2026 Business Separation
Becton Dickinson Analyst Price Target Narrative Update The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term. Analyst Commentary Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities.Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Los dividendos por acción de BDX se han mantenido estables en los últimos 10 años.
Dividendo creciente: El pago de dividendos de BDX ha aumentado en los últimos 10 años.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de Becton Dickinson vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (BDX) | 2.4% |
| Suelo de mercado 25% (US) | 1.4% |
| Techo de mercado 25% (US) | 4.1% |
| Media de la industria (Medical Equipment) | 2.0% |
| Analista de previsiones (BDX) (hasta 3 años) | 2.2% |
Dividendo destacado: El dividendo de BDX(2.36%) es más alto que el 25% inferior de los pagadores de dividendos del mercado US (1.36%).
Alto dividendo: El (2.36%) del dividendo de BDX es bajo en comparación con el 25% de los principales pagadores de dividendos del mercado US (4.11%).
Pago de beneficios a los accionistas
Cobertura de los beneficios: Con su razonable ratio de pago (71.7%), los pagos de dividendos de BDX están cubiertos por los beneficios.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Con su razonablemente bajo ratio de pago en efectivo (44.2%), los pagos de dividendos de BDX están bien cubiertos por los flujos de caja.
Descubre empresas que pagan buenos dividendos
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/14 07:33 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/09/30 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Becton, Dickinson and Company está cubierta por 31 analistas. 12 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Adam Feinstein | Barclays |